Premium
Deficiency of polycystin‐2 reduces Ca 2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells
Author(s) -
Aguiari Gianluca,
Banzi Manuela,
Gessi Stefania,
Cai Yiqiang,
Zeggio Emanuela,
Manzati Elisa,
Piva Roberta,
Lambertini Elisabetta,
Ferrari Luisa,
Peters Dorien J.,
Lanza Francesco,
Harris Peter C.,
Borea Pier Andrea,
Somlo Stefan,
Senno Laura
Publication year - 2004
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.03-0687fje
Subject(s) - pkd1 , autosomal dominant polycystic kidney disease , polycystic kidney disease , hek 293 cells , biology , microbiology and biotechnology , intracellular , cell growth , kidney , gene , endocrinology , biochemistry
Polycystin‐2 (PC2), encoded by the PKD2 gene, mutated in 10‐15% of autosomal‐dominant polycystic kidney disease (ADPKD) patients, is a Ca 2+ ‐permeable cation channel present in kidney epithelia and other tissues. As PC2 was found expressed in B‐lymphoblastoid cells (LCLs) and Ca 2+ signaling pathways are important regulators of B cell function activities, we investigated whether PC2 plays some role in B‐LCLs. In LCLs, PC2 was found mainly in ER membranes but ~8 times less than in kidney HEK293 cells. The same reductions were found in PKD2 and PKD1 RNA; thus, PKD genes maintained, in LCLs, the same reciprocal proportion as they do in kidney cells. In LCLs obtained from subjects carrying PKD2 mutations (PKD2‐LCLs) and showing reduced PC2 levels, intracellular Ca 2+ concentrations evoked by platelet‐activating factor (PAF), were significantly lower than in non‐PKD‐LCLs. This reduction was also found in PKD1‐ LCLs but without PC2 reductions. Likewise, cell proliferation, which is controlled by Ca 2+ , was reduced in PKD2‐ and PKD1‐LCLs. Moreover, in LCLs with PKD2 nonsense mutations, aminoglycoside antibiotics reduced the PC2 defect by promoting readthrough of stop codons. Therefore, PC2 and PC1 are functionally expressed in LCLs, which provide a model, easily obtainable from ADPKD patients, to study PKD gene expression and function.